西妥昔单抗与放疗在头颈部肿瘤中的教条——从黎明到黄昏的旅程
本文综述西妥昔单抗联合放疗(Bio-Radiotherapy,BRT)在局部晚期头颈部鳞状细胞癌(LA-HNSCC)中的角色演变。西妥昔单抗BRT曾被视为标准治疗之一,但多项III期临床试验结果公布后并不令人鼓舞,西妥昔单抗未能胜过顺铂为基础的放化疗这一当前标准治疗。作者认为需根据最新临床证据重新评估西妥昔单抗在LA-HNSCC根治性治疗中的现有地位。
要点
- 西妥昔单抗联合放疗曾被认为是LA-HNSCC的标准治疗模式之一。
- 多项III期临床试验结果公布后并不令人鼓舞。
- 西妥昔单抗未能胜过顺铂为基础的放化疗这一当前标准治疗。
核心结论
- 西妥昔单抗联合放疗在初始成功后未能胜过顺铂为基础的放化疗,后者是LA-HNSCC当前的标准治疗。
- 作者认为需根据最新临床证据重新评估和界定西妥昔单抗在LA-HNSCC根治性治疗中的现有角色。
研究设计与样本
- 本文为综述,围绕西妥昔单抗联合放疗(BRT)在头颈部肿瘤中的应用,汇总多项同时期开展的III期临床试验结果。
主要发现
- EGFR表达与放射抗拒和不良预后相关,因此在放疗中加入抗EGFR药物是逻辑上合理且有吸引力的选择。
- 西妥昔单抗联合放疗作为生物放疗(BRT)曾被认为是LA-HNSCC的标准治疗模式之一。
- 多项重要III期临床试验同时开展,在不同临床场景和不同假设下检验西妥昔单抗BRT。
- 在 studies 仍在进行、结果待出期间,其临床应用仍在继续;如今结果已公布,明确并不令人鼓舞。
- 西妥昔单抗在初始成功后未能胜过顺铂为基础的放化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the introduction of Cetuximab as a biological molecule against Epidermal Growth Factor Receptor (EGFR), its use in the cancers of head and neck region is widely explored. With the recognition that EGFR expression is associated with radioresistance and poor prognosis, incorporation of an anti-EGFR agent along with Radiotherapy (RT) is a logical and attractive option. Cetuximab in combination with RT as Bio-Radiotherapy (BRT) is considered one of the standard treatment modalities in Locally Advanced Head and Neck Squamous Cell Cancers (LA-HNSCC). Many important phase-III clinical trials were undertaken simultaneously, where the use of Cetuximab BRT was tested in various clinical scenarios with different hypothesis. With the studies still ongoing and the results awaited, its use was continued in clinical practice. Today the results are out and definitely not encouraging. After the initial success, Cetuximab has miserably failed to win over cisplatin based chemoradiation which is the current standard of care in LA-HNSCC. Hence, it is the need of the hour to re-evaluate and define the present role of Cetuximab in the definitive management of LA-HNSCC in the light of the latest clinical evidence..
引用
- Krishnamurthy S, Ahmed I, Bhise R, et al. The dogma of Cetuximab and Radiotherapy in head and neck cancer - A dawn to dusk journey. Clin Transl Radiat Oncol. 2022. PMID: 35356388. doi:10.1016/j.ctro.2022.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。